Literature DB >> 27895769

Unusual lower back pain with monocytosis: A case report.

Sheng-Cheng Wu1, Tzu-Chuan Huang1, Wen-Ya Yu1, Yi-Ying Wu1.   

Abstract

There are numerous causes of lower back pain. In the oncological setting, spine metastasis from a solid tumor is the most common. However, hematological disorders should also be taken into consideration. The current study presents a case of chronic myelomonocytic leukemia with the initial presentation of chronic lower back pain, followed by symptoms that included urinary retention, stool incontinence and left gum swelling, in a patient who was eventually diagnosed with granulocytic sarcoma (GS) over the sacral region. GS is a rare presentation of a tumor consisting of extramedullary leukemic infiltrations, which develop at different sites and cause different symptoms. Prompt and correct diagnosis of this type of disease may be crucial to improve the survival outcome by the early initiation of adequate treatment.

Entities:  

Keywords:  back pain; chronic myelomonocytic leukemia; granulocytic sarcoma

Year:  2016        PMID: 27895769      PMCID: PMC5104231          DOI: 10.3892/ol.2016.5190

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  17 in total

Review 1.  Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.

Authors:  Sameer A Parikh; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2013-11       Impact factor: 10.047

2.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

Authors:  Lewis R Silverman; David R McKenzie; Bercedis L Peterson; James F Holland; Jay T Backstrom; C L Beach; Richard A Larson
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

Review 3.  Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature.

Authors:  Rahel A Mathew; John M Bennett; Jane Jijun Liu; Rami S Komrokji; Jeffrey E Lancet; Mojdeh Naghashpour; Jane L Messina; Alan F List; Lynn C Moscinski; Ling Zhang
Journal:  Leuk Res       Date:  2011-07-22       Impact factor: 3.156

4.  Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.

Authors:  Esperanza Such; Ulrich Germing; Luca Malcovati; José Cervera; Andrea Kuendgen; Matteo G Della Porta; Benet Nomdedeu; Leonor Arenillas; Elisa Luño; Blanca Xicoy; Mari L Amigo; David Valcarcel; Kathrin Nachtkamp; Ilaria Ambaglio; Barbara Hildebrandt; Ignacio Lorenzo; Mario Cazzola; Guillermo Sanz
Journal:  Blood       Date:  2013-01-31       Impact factor: 22.113

Review 5.  Skeletal complications of malignancy.

Authors:  R E Coleman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

Review 6.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

7.  Renal involvement by chronic myelomonocytic leukemia requiring nephroureterectomy.

Authors:  Elias S Hyams; Raavi Gupta; Jonathan Melamed; Samir S Taneja; Ojas Shah
Journal:  Rev Urol       Date:  2009

8.  Pericardial extramedullary haemopoiesis in chronic myelomonocytic leukaemia.

Authors:  C R Bradford; S R Smith; J P Wallis
Journal:  J Clin Pathol       Date:  1993-07       Impact factor: 3.411

9.  Isolated CNS relapse following stem cell transplantation for juvenile myelomonocytic leukemia.

Authors:  David B Wilson; Jeff M Michalski; William J Grossman; Robert J Hayashi
Journal:  J Pediatr Hematol Oncol       Date:  2003-11       Impact factor: 1.289

Review 10.  Current paradigms for metastatic spinal disease: an evidence-based review.

Authors:  P E Kaloostian; A Yurter; P L Zadnik; D M Sciubba; Z L Gokaslan
Journal:  Ann Surg Oncol       Date:  2013-10-22       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.